Sino Biopharmaceutical
Sino Biopharmaceutical Limited, commonly referred to as Sino Biopharmaceutical, is a leading player in the pharmaceutical preparation manufacturing industry, headquartered in Hong Kong. Established in 1996, the company has made significant strides in developing innovative medicines, particularly in the fields of oncology, cardiovascular, and central nervous system disorders.
With a robust presence in major operational regions across China and expanding internationally, Sino Biopharmaceutical is renowned for its commitment to research and development. The company’s core products include a diverse range of prescription medications and therapeutic solutions, distinguished by their high quality and efficacy.
Sino Biopharmaceutical has achieved notable market recognition, positioning itself among the top pharmaceutical manufacturers in China, and continues to drive advancements in healthcare through its dedication to innovation and excellence.
-11 vs industry average
Sino Biopharmaceutical’s score of 27 is lower than 42% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Part of the Sustainability team at Sino Biopharmaceutical?
- Control how your company's emission story is told
- Respond to customers efficiently
- See who's viewing your profile
Industry Intensity
Pharmaceutical Preparation Manufacturing has below-average carbon intensity
Industry performance
The Pharmaceutical Preparation Manufacturing industry has reduced its overall emissions by 19% since 0
Emissions trajectory 2020 – 2027
Reported emissions
Scope 3 accounts for ••• of total emissions.
Sino Biopharmaceutical's reported carbon emissions
Sino Biopharmaceutical: Emissions and Climate Commitments (2018-2024)
Hong Kong-based Sino Biopharmaceutical, a key player in the Pharmaceutical Preparation Manufacturing industry, has been tracking its carbon emissions with increasing detail.
Emissions Data:
- 2024: Sino Biopharmaceutical reported a total of approximately 208.2 million kg CO2e. This comprised about 18.2 million kg CO2e of Scope 1 emissions and approximately 189.9 million kg CO2e of Scope 2 emissions. Scope 3 emissions data for this year was not disclosed.
- 2023: Total emissions for 2023 stood at roughly 239.2 million kg CO2e. Scope 1 emissions accounted for about 17.0 million kg CO2e, with Scope 2 emissions totalling approximately 222.1 million kg CO2e. Scope 3 emissions were not reported.
- 2022: The company's emissions in 2022 were approximately 277.0 million kg CO2e, including about 16.0 million kg CO2e from Scope 1 and roughly 260.9 million kg CO2e from Scope 2. Scope 3 data was unavailable.
- 2021: In 2021, Sino Biopharmaceutical reported emissions of approximately 274.9 million kg CO2e, with Scope 1 at about 21.7 million kg CO2e and Scope 2 at approximately 253.2 million kg CO2e. Scope 3 emissions were not disclosed.
- 2020: Total emissions for 2020 were approximately 221.6 million kg CO2e. Specific breakdown for Scope 1 and Scope 2 was not available, and Scope 3 was not reported.
- 2019: Emissions in 2019 were approximately 189.5 million kg CO2e. Scope 1, Scope 2, and Scope 3 data were not disclosed.
- 2018: The company reported total emissions of approximately 120.3 million kg CO2e in 2018. Detailed scope-specific data was not available.
Climate Commitments and Reduction Initiatives:
Sino Biopharmaceutical has set a near-term intensity reduction target. The company aims to reduce its greenhouse gas (GHG) emissions per RMB1 million of revenue by 20% by 2025, using 2021 as the benchmark year.
While Scope 3 emissions are currently not disclosed, the company's reporting indicates a focus on tracking and potentially managing emissions across its operations. The availability of Scope 1 and Scope 2 data, along with intensity metrics, suggests a commitment to understanding and influencing its environmental footprint within the pharmaceutical sector.
Unlock detailed emission data
Access structured emission data, company specific factors and auditable source documents
Sino Biopharmaceutical’s Climate Goals (2030 & 2050)
1 goal2025
20% reduction in all scopes
Reduce GHG emissions per RMB1 million of revenue by 2025 with 2021 as the year of benchmark
2030
62% reduction in total GHG
Vs 2019 baseline. Validated by SBTi. Includes full supply chain.
2040
50% reduction in Scope 3 intensity
Across purchased goods and services and logistics.
See all 1 climate goals
Already have an account? Sign in now
Scope 3 top emissions categories
No scope 3 category breakdown has been disclosed yet.
Climate initiatives

Science Based Targets Initiative

Carbon Disclosure Project
The Climate Pledge
UN Global Compact Climate Champions initiative
RE 100
Climate Action 100
Emissions comparison with industry peers
View similar organisationsUsage policy
You’re welcome to quote or reference data from this page, but please include a visible link back to this URL. Bulk collection, resale, or redistribution of data from multiple profiles is not permitted.
See our License Agreement for more details.
Where does DitchCarbondata come from?
Discover our data-driven methodology for measuring corporate climate action and benchmarking against industry peers
Learn moreCurious to see your top suppliers emissions?
Book a demo for a pilot project